Advanced drug delivery systems utilize various mechanisms for targeting cancer cells. These include passive targeting, where nanocarriers exploit the enhanced permeability and retention (EPR) effect of tumors, and active targeting, where ligands or antibodies on the carrier surface bind specifically to receptors on cancer cells.
